vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and LendingClub Corp (LC). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $252.3M, roughly 1.1× LendingClub Corp). LendingClub Corp runs the higher net margin — 20.5% vs -45.7%, a 66.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 15.9%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 16.1%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
LendingClub Corporation is an American financial services company headquartered in San Francisco, California. It was the first peer-to-peer lender to register its offerings as securities with the Securities and Exchange Commission (SEC), and to offer loan trading on a secondary market. At its height, LendingClub was the world's largest peer-to-peer lending platform. The company reported that $15.98 billion in loans had been originated through its platform up to December 31, 2015.
GH vs LC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $252.3M |
| Net Profit | $-128.5M | $51.6M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | 20.5% |
| Revenue YoY | 39.4% | 15.9% |
| Net Profit YoY | -15.8% | 341.0% |
| EPS (diluted) | $-1.01 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $252.3M | ||
| Q4 25 | $281.3M | $266.5M | ||
| Q3 25 | $265.2M | $266.2M | ||
| Q2 25 | $232.1M | $248.4M | ||
| Q1 25 | $203.5M | $217.7M | ||
| Q4 24 | $201.8M | $217.2M | ||
| Q3 24 | $191.5M | $201.9M | ||
| Q2 24 | $177.2M | $187.2M |
| Q1 26 | — | $51.6M | ||
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $44.3M | ||
| Q2 25 | $-99.9M | $38.2M | ||
| Q1 25 | $-95.2M | $11.7M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $14.5M | ||
| Q2 24 | $-102.6M | $14.9M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | -43.0% | 18.8% | ||
| Q3 25 | -37.3% | 21.5% | ||
| Q2 25 | -45.9% | 21.7% | ||
| Q1 25 | -54.6% | 7.2% | ||
| Q4 24 | -62.4% | 5.1% | ||
| Q3 24 | -61.3% | 8.9% | ||
| Q2 24 | -56.8% | 10.4% |
| Q1 26 | — | 20.5% | ||
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | 16.6% | ||
| Q2 25 | -43.0% | 15.4% | ||
| Q1 25 | -46.8% | 5.4% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | 7.2% | ||
| Q2 24 | -57.9% | 8.0% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $-1.01 | $0.36 | ||
| Q3 25 | $-0.74 | $0.37 | ||
| Q2 25 | $-0.80 | $0.33 | ||
| Q1 25 | $-0.77 | $0.10 | ||
| Q4 24 | $-0.90 | $0.08 | ||
| Q3 24 | $-0.88 | $0.13 | ||
| Q2 24 | $-0.84 | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | — |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.5B |
| Total Assets | $2.0B | $11.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | — | ||
| Q2 25 | $629.1M | — | ||
| Q1 25 | $698.6M | — | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | — | ||
| Q2 24 | $933.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $0 | ||
| Q3 25 | $1.1B | $0 | ||
| Q2 25 | $1.1B | $0 | ||
| Q1 25 | $1.1B | $0 | ||
| Q4 24 | $1.1B | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $-99.3M | $1.5B | ||
| Q3 25 | $-354.5M | $1.5B | ||
| Q2 25 | $-305.5M | $1.4B | ||
| Q1 25 | $-250.8M | $1.4B | ||
| Q4 24 | $-139.6M | $1.3B | ||
| Q3 24 | $-60.1M | $1.3B | ||
| Q2 24 | $-1.6M | $1.3B |
| Q1 26 | — | $11.9B | ||
| Q4 25 | $2.0B | $11.6B | ||
| Q3 25 | $1.3B | $11.1B | ||
| Q2 25 | $1.3B | $10.8B | ||
| Q1 25 | $1.3B | $10.5B | ||
| Q4 24 | $1.5B | $10.6B | ||
| Q3 24 | $1.5B | $11.0B | ||
| Q2 24 | $1.6B | $9.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $-2.7B | ||
| Q3 25 | $-35.4M | $-770.8M | ||
| Q2 25 | $-60.3M | $-713.1M | ||
| Q1 25 | $-62.7M | $-339.3M | ||
| Q4 24 | $-64.5M | $-2.6B | ||
| Q3 24 | $-51.1M | $-669.8M | ||
| Q2 24 | $-94.0M | $-932.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $-2.9B | ||
| Q3 25 | $-45.8M | $-791.8M | ||
| Q2 25 | $-65.9M | $-803.8M | ||
| Q1 25 | $-67.1M | $-352.3M | ||
| Q4 24 | $-83.4M | $-2.7B | ||
| Q3 24 | $-55.3M | $-682.3M | ||
| Q2 24 | $-99.1M | $-945.3M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | -1076.0% | ||
| Q3 25 | -17.3% | -297.4% | ||
| Q2 25 | -28.4% | -323.5% | ||
| Q1 25 | -33.0% | -161.8% | ||
| Q4 24 | -41.3% | -1237.8% | ||
| Q3 24 | -28.9% | -338.0% | ||
| Q2 24 | -55.9% | -504.9% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 52.7% | ||
| Q3 25 | 3.9% | 7.9% | ||
| Q2 25 | 2.4% | 36.5% | ||
| Q1 25 | 2.2% | 6.0% | ||
| Q4 24 | 9.4% | 25.0% | ||
| Q3 24 | 2.2% | 6.2% | ||
| Q2 24 | 2.9% | 6.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -17.41× | ||
| Q2 25 | — | -18.68× | ||
| Q1 25 | — | -29.07× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -46.33× | ||
| Q2 24 | — | -62.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
LC
Segment breakdown not available.
